Pain management

SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology

Retrieved on: 
Wednesday, March 6, 2024
Central nervous system, Opioid, TEL, Pain, Patent, Chronic pain, Pain management, Patient, Disorder, Legislation, Pharmaceutical industry

The Patent has been granted by the Canadian Intellectual Property Office, the government agency in Canada that administers intellectual property rights and legislation for patents.

Key Points: 
  • The Patent has been granted by the Canadian Intellectual Property Office, the government agency in Canada that administers intellectual property rights and legislation for patents.
  • "With the Canadian patent approval for our opioid reduction technology, SciSparc continues to build on global recognition of its innovations and breakthrough technologies.
  • We are all aware of how effective opiates are in relieving pain, but also for their addictive influence.
  • Our technology represents hope for safer and more effective pain management strategies worldwide," said SciSparc’s Chief Executive Officer, Oz Adler.

Brains Bioceutical Corp, the Global Leader in Natural Cannabinoid APIs, Introduces Revolutionary Solid THC, Ushering in a New Era of Clinical Research

Retrieved on: 
Tuesday, March 5, 2024
Mental health, Active ingredient, USD, API, Quality of life, Drug development, Hope, Pharmacy, Safety, Pain management, JCAC, D9, Health, Patient, THC, Medicine, Veteran, DSM-IV codes, Cannabis, Face

This milestone reflects the company's commitment to innovation and its position at the forefront of the cannabinoid pharmaceutical industry.

Key Points: 
  • This milestone reflects the company's commitment to innovation and its position at the forefront of the cannabinoid pharmaceutical industry.
  • This breakthrough not only signifies a significant advancement in cannabinoid research but also underscores our commitment to driving innovation in pharmaceuticals.” Ricky Brar CEO & Chairman of Brains Bio.
  • "As a scientist deeply involved in cannabinoid research, I am thrilled by Brains Bio announcement of the solid D9 THC API.
  • The solid D9 THC is not just a product; it’s a symbol of Brains Bio commitment to pioneering the future of healthcare and pharmaceuticals.

Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

Retrieved on: 
Monday, March 4, 2024
Therapy, Life, PALO, Health, Safety, Growth, Chronic pain, Publication, Pain management, Patient, Nursing

The new website has been designed to offer the ultimate viewer-friendly experience with improved navigation and functionality, while allowing viewers to see the full commercial product portfolio as well as product candidates provided by Scilex.

Key Points: 
  • The new website has been designed to offer the ultimate viewer-friendly experience with improved navigation and functionality, while allowing viewers to see the full commercial product portfolio as well as product candidates provided by Scilex.
  • The website also provides an extensive knowledge base of acute and chronic pain management, bringing increased clarity to the otherwise complicated nature of specialty pharmaceuticals.
  • "The new website conveys how we're translating our technologies into meaningful non-opioid products and pipeline to address the opioid crisis with significant real-world impact.
  • For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com .

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024
Acquisition, Conference call, Expansion, New Drug Application, Suite, Food, FDA, Growth, Shanda, Bupivacaine, Novo Nordisk, Conference, Genentech, GAAP, Roche, Pain management, Therapy, Patient, Cancer

TAMPA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2023.

Key Points: 
  • ET —
    TAMPA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2023.
  • Fourth quarter 2023 iovera° net product sales were $6.0 million, a 32% increase over the $4.6 million reported in the fourth quarter of 2022.
  • Total operating expenses were $148.1 million in the fourth quarter of 2023, versus the $181.8 million reported for the fourth quarter of 2022.
  • Cash provided by operations was $47.6 million in the fourth quarter of 2023, compared to $42.0 million in the fourth quarter of 2022.

Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)

Retrieved on: 
Tuesday, February 27, 2024
PALO, AAPM, Neuropathic pain, First, MST, Chronic pain, Pain management, Patient, Poster, Lidocaine, American Academy, Birth control

Titled: Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (First author: Srinivas Nalamachu, M.D.).

Key Points: 
  • Titled: Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (First author: Srinivas Nalamachu, M.D.).
  • In addition, patients treated with ZTlido® had a more significant reduction in opioid dose relative to a generic lidocaine 5% patch.
  • Regardless of the type of neuropathic pain, ZTlido® was associated with a greater opioid-sparing effect than a generic lidocaine 5% patch.
  • As a result, improved adhesion for ZTlido® is likely contributing to more optimal pain management and enable reduction/discontinuation of opioid dose.

Strainsforpains Inc. Announces Corporate Update

Retrieved on: 
Friday, February 23, 2024
Hospital, Media, Intelligence, Absorption, Growth, International Cannabinoid Research Society, Pain management, Nursing, Patient, Security (finance), Glaucoma, Research

Strainsforpains is pleased to announce that it has increased the capacity of its Pennsylvania facility to accommodate the company’s growing CBD product line.

Key Points: 
  • Strainsforpains is pleased to announce that it has increased the capacity of its Pennsylvania facility to accommodate the company’s growing CBD product line.
  • Based on updated preliminary orders, Strainsforpains foresees CBD sales exceeding $500,000 for fiscal 2024.
  • Strainsforpains, Inc. is an innovative healthcare data technology Company located in New York, N.Y.
  • Although Strainsforpains, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Strainsforpains, Inc. is unable to give any assurance that its expectations will be attained.

AIS Healthcare Recognizes Brain Injury Awareness Month

Retrieved on: 
Thursday, March 7, 2024
Health, Consumer, Other Health, General Health, Pharmaceutical, People with Disabilities, Brain damage, Quality of life, TBI, Chronic pain, Pain management, Patient, Family, Brain, CDC, TDD, Research, Medical device

AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March as Brain Injury Awareness Month.

Key Points: 
  • AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March as Brain Injury Awareness Month.
  • This month reminds us of the importance of improving the quality of life for people impacted by brain injury through elevating awareness and advocacy and delivering the highest-quality healthcare.
  • “This month and every month, we seek to empower individuals living with a brain injury by delivering the best possible in-home healthcare services and pain management solutions.
  • To find more ways to support the brain injury community, contact your local brain injury association by visiting here .

ESO Appoints Brandon Martinez as Chief Innovation Officer, Driving Strategic Technology Innovation supporting the EMS, Fire, Hospital Industries

Retrieved on: 
Thursday, March 7, 2024
Health Technology, Data Management, State, Local, Manufacturing, Technology, Law Enforcement, Emergency Services, Public Safety, General Health, Professional Services, Hospitals, Public Policy, Government, Artificial Intelligence, Machinery, Software, Data Analytics, Health, Bias, Hospital, Emergency medical services, Research, Multimedia, Culture, Generative, Synthetic media, Safety, Martínez, Head, Pain management, Machine learning, CIO, EMS, ESO, Management

View the full release here: https://www.businesswire.com/news/home/20240307308402/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307308402/en/
    Brandon Martinez takes on role of Chief Innovation Officer, a strategic moving to bring technology like responsible Generative AI and machine learning into the ESO product suite.
  • (Photo: Business Wire)
    Martinez's new role signifies a deliberate focus on innovation within ESO.
  • "Emerging technologies such as Generative AI have the potential to revolutionize entire categories of software products, including those within the healthcare and public safety markets we serve,” said Brandon Martinez, Chief Innovation Officer at ESO.
  • “At ESO, we recognize the importance of innovation in driving progress and meeting the evolving needs of our customers.

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

Retrieved on: 
Tuesday, February 27, 2024
Other Health, General Health, Professional Services, Pharmaceutical, Medical Devices, Infectious Diseases, Hospitals, Science, Legal, Biotechnology, Practice Management, Health, Other Science, Central nervous system, Plaintiff, Pain management, Post-traumatic stress disorder, Therapy, CNS, IND

The term sheet sets forth the principal terms of a mutual release and settlement agreement to be entered into by the Company and the Plaintiffs.

Key Points: 
  • The term sheet sets forth the principal terms of a mutual release and settlement agreement to be entered into by the Company and the Plaintiffs.
  • However, if the parties fail to do so by or before March 1, 2024, the term sheet will become binding.
  • Plaintiff’s release of Virpax is conditioned upon Virpax making its initial payment.
  • “I am pleased that we were able to bring this litigation to a satisfactory conclusion,” stated Gerald Bruce, CEO of Virpax Pharmaceuticals.

Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Health, Science, Other Science, Pharmaceutical, Transfer, Central nervous system, Special, Common stock, Exercise, Common, CUSIP, Pain management, Post-traumatic stress disorder, CNS

The new CUSIP number for the Common Stock following the reverse split will be 928251206.

Key Points: 
  • The new CUSIP number for the Common Stock following the reverse split will be 928251206.
  • We believe this reverse split will allow us to regain compliance with Nasdaq’s minimum bid price requirement and to make our bid price more attractive to a broader universe of investors.
  • Stockholders whose shares are held in brokerage accounts should direct any questions concerning the reverse stock split to their broker.
  • The Nasdaq Capital Market requires, among other things, that a listed company’s common stock maintain a minimum bid price of at least $1.00 per share.